A capsule formulation of pirfenidone is provided that includespharmaceutically acceptable excipients. In one embodiment, this capsuleformulation is capable of sustaining desirable pharmacokinetic responses in apatient. Further provided are methods of treating fibrotic conditions andother cytokine-mediated disorders by administering pirfenidone capsules ofsuch formulation to a patient in need.